Gsa Capital Partners LLP Surface Oncology, Inc. Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.61 - $1.03 $28,127 - $47,494	-46,111 Reduced 16.68%	230,292 $161,000
Q4 2022 Feb 13, 2023	BUY	$0.62 - $1.21 $96,732 - $188,784	156,020 Added 129.6%	276,403 $227,000
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.1 $62,783 - $125,567	59,794 Added 98.69%	120,383 $125,000
Q2 2022 Aug 09, 2022	BUY	$1.42 - $3.15 $46,889 - $104,016	33,021 Added 119.78%	60,589 $99,000
Q1 2022 May 11, 2022	BUY	$2.65 - $5.08 $73,055 - $140,045	27,568 New	27,568 $81,000
Q3 2021 Nov 12, 2021	SELL	$5.16 - $7.98 $594,158 - $918,873	-115,147 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$6.45 - $9.09 $742,698 - $1.05 Million	115,147 New	115,147 $859,000
Q1 2021 May 10, 2021	SELL	$7.25 - $13.82 $193,749 - $369,325	-26,724 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$6.87 - $10.48 $183,593 - $280,067	26,724 New	26,724 $247,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.